GlycoMimetics rises after encouraging data from leukemia drug trial
23/09/2021 21:58
** Shares of drug developer GLYC.O up nearly 15% at $2.55
in extended trading
** Co announces positive efficacy and safety data from Phase
1/2 clinical study for lead investigational drug uproleselan
urn:newsml:reuters.com:*:nBwbs0Cyja
** Uproleselan is GLYC's investigational drug for treatment
of leukemia
** "We are confident that our ongoing Phase 3 randomized
trial will confirm the efficacy seen in the Phase 1/2 study,"
Chief Medical Officer Eric Feldman says
** Consensus rating on stock is "buy", with median PT of $14
** YTD, stock has plunged 39%
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering